Skip to main content
. 2010 Jan;1(1):26–39. doi: 10.1177/1947601909358184

Figure 7.

Figure 7.

KIF18A physically interacts with BubR1 and CENP-E. (A) Control HeLa cells or the cells treated with paclitaxel or transfected with KIF18A siRNA for 24 h were subjected to chromosome spread analysis. Representative mitotic chromosomes from each treatment are shown. (B) HeLa cells treated with paclitaxel or transfected with KIF18A siRNA for 24 h were subjected to chromosome spread analysis. The percentages of normal chromosomes and chromosomes with premature sister chromatid separation were summarized from 3 independent experiments. (C) Equal amounts of interphase cell or mitotic cell (Taxol-treated) lysates were subjected to immunoprecipitation using the KIF18A antibody or a control IgG. Immunoprecipitates, along with the lysate inputs, were blotted for KIF18A, BubR1, and Eg5. Arrow p-BubR1 denotes the phosphorylated BubR1. (D) Equal amounts of interphase cell or mitotic cell (Taxol-treated) lysates were subjected to immunoprecipitation using the KIF18A antibody or a control IgG. Immunoprecipitates and the lysate inputs were blotted for KIF18A and CENP-E. Each experiment was repeated for at least 3 times. Representative data are shown.